Latest / The Well-Built Life / GLP-1: Beyond Diabetes—Cognition and Memory
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:09Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:13Speaker 1: share simple, practical habits that help you feel stronger, healthier,
- 0:17Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:22Speaker 1: and let's dive in. All right, Thomas. Let's dive into
- 0:26Speaker 1: the fascinating journey of GLP-1 from diabetes management to cognitive enhancement.
- 0:32Speaker 1: It's like a narrative that starts with one problem and
- 0:36Speaker 1: ends up with a plethora of potential solutions.
- 0:39Speaker 2: Exactly, because on the surface it looks straightforward, but when
- 0:42Speaker 2: you dig into the mechanics, the incentives tell a very
- 0:46Speaker 2: different story. Let's start with the initial drug discoveries, exenatide.
- 0:51Speaker 2: The first in this class hit the market for managing
- 0:54Speaker 2: type 2 diabetes, and it sure did a bang-up job.
- 0:57Speaker 1: Right. If you look at the capital flows over the
- 0:59Speaker 1: past decade, it was all about weight loss and glucose control.
- 1:03Speaker 1: But just as the patent was about to expire, pharmaceutical
- 1:07Speaker 1: companies took a keen interest in the cognitive benefits they
- 1:09Speaker 1: noticed died effects, like improved mood and memory, that weren't
- 1:13Speaker 1: initially part of the research criteria.
- 1:15Speaker 2: That's wild when you look at the raw numbers. Animal
- 1:18Speaker 2: studies showed some promising memory enhancements, and they sparked enough
- 1:22Speaker 2: curiosity to warrant further investigation in humans. The term micro-doping
- 1:28Speaker 2: started to pop up in forums and social media, referring
- 1:31Speaker 2: to the unapproved use of GLP-1 as a cognitive enhancer.
- 1:36Speaker 1: Exactly. Which brings up an interesting contradiction. While it's clear
- 1:41Speaker 1: that GLP-1 has a primary role in appetite and glucose regulation,
- 1:46Speaker 1: its peripheral and central actions hint at a more nuanced
- 1:49Speaker 1: impact on the brain. The vagus nerve through which GLP-1
- 1:53Speaker 1: communicates is crucial for satiation and appetite control, but it's
- 1:59Speaker 1: also a key player in reward pathways and memory formation.
- 2:03Speaker 2: Absolutely. Take the case of GLP-1, S interaction with the gut,
- 2:09Speaker 2: brain axis. It's fascinating how GLP-1 secreted in the intestines
- 2:14Speaker 2: can also influence the brain, and vice versa. For instance,
- 2:19Speaker 2: studies by Dr. Huberman and Dr. Kanowski found that GLP-1
- 2:24Speaker 2: might have a role in regulating memory and reward processing.
- 2:28Speaker 2: But HERA's a rub. They are still trying to understand
- 2:32Speaker 2: the mechanisms behind these effects, especially in terms of long-term
- 2:36Speaker 2: cognitive benefits.
- 2:38Speaker 1: Right. And the debate around microdosing isn't just about the
- 2:41Speaker 1: perceived benefits. The risks and side effects can't be ignored.
- 2:46Speaker 1: especially when we are talking about off-label use. The study
- 2:49Speaker 1: suggests that while some individuals report improved focus and memory,
- 2:54Speaker 1: there are still questions about whether these effects are robust
- 2:58Speaker 1: and long-lasting.
- 2:59Speaker 2: That's a key point. We need more randomized controlled trials
- 3:02Speaker 2: to validate these claims. But Therese no denying the excitement
- 3:06Speaker 2: in the scientific community. The potential applications could be game-changing,
- 3:10Speaker 2: not just for weight loss but for treating cognitive impairments
- 3:14Speaker 2: and disorders like Alzheimer's.
- 3:16Speaker 1: Absolutely, and let's not forget the ethical considerations. Micro, dosing
- 3:20Speaker 1: at home, let alone in clinical settings, raises significant issues.
- 3:25Speaker 1: What are the long-term consequences of chronic DLP-1 exposure? Are
- 3:30Speaker 1: these benefits worth the risks? These are questions we will
- 3:33Speaker 1: be grappling with for years to come. Indeed.
- 3:36Speaker 2: But it's also promising that the research is ongoing, and
- 3:39Speaker 2: scientists are getting closer to unraveling the complex dance of
- 3:43Speaker 2: GLP-1 in the brain. With new targeted receptor agonists, we
- 3:48Speaker 2: might see more specific treatments for a range of conditions,
- 3:52Speaker 2: from obesity to perhaps even neurodegenerative diseases.
- 3:55Speaker 1: That's the hopeful part. Whether or not GLP-1 becomes a
- 4:00Speaker 1: household name like insulin, its journey so far is quite remarkable.
- 4:05Speaker 1: This is a story of innovation and adaptability, driven by
- 4:09Speaker 1: the ever-evolving landscape of health research. So, let's break down
- 4:14Speaker 1: the mechanics of GLP-1. We know it's secreted in the
- 4:18Speaker 1: intestines and brain. But how does it actually get to
- 4:22Speaker 1: the brain? And what's the mechanism behind its secretion?
- 4:25Speaker 2: Right. It's fascinating. GLP-1 is primarily secreted in the distal
- 4:31Speaker 2: intestines during glucose ingestion. where it binds to receptors on
- 4:35Speaker 2: the vagus nerve to signal satiety. This mechanism is crucial
- 4:39Speaker 2: for appetite control. But here is the interesting part. DLP-1
- 4:45Speaker 2: also has receptors on neurons in the brainstem, specifically in
- 4:49Speaker 2: areas like the hypothalamus and nucleus tractus solitary. This is
- 4:54Speaker 2: where its effects on glucose homeostasis and appetite suppression are
- 4:58Speaker 2: most studied.
- 4:59Speaker 1: That's a crucial nuance. And what about the role of
- 5:02Speaker 1: the vagus nerve more directly? How does it play a
- 5:06Speaker 1: part in the GLP-1 mechanism?
- 5:08Speaker 2: Great question. The vagus nerve acts like a pathway between
- 5:12Speaker 2: the gut and the brain. When GLP-1 binds to its
- 5:16Speaker 2: receptors on the vagal nerve, it triggers a cascade of
- 5:20Speaker 2: signals that reduce appetite and contribute to satiation. In essence,
- 5:24Speaker 2: it's like a built-in mechanism to regulate diet and weight.
- 5:28Speaker 1: Onwards, then, to the brain itself.
- 5:36Speaker 2: Well, this is where the story gets particularly intriguing. GLP-1
- 5:42Speaker 2: is also involved in the brain's reward pathways. It binds
- 5:45Speaker 2: to receptors in areas like the nucleus accumbens, which plays
- 5:49Speaker 2: a key role in reward and motivation. Preliminary findings suggest
- 5:54Speaker 2: that GLP-1 could potentially enhance the release of neurotransmitters like dopamine.
- 6:00Speaker 2: which is linked to memory formation and reward.
- 6:03Speaker 1: That's wild when you look at the raw numbers. What
- 6:06Speaker 1: about the potential side effects? And how safe is this
- 6:09Speaker 1: for cognitive use?
- 6:11Speaker 2: Safety is a big concern. Early GLP-1 drugs like exenatide
- 6:16Speaker 2: did come with side effects, particularly nausea and vomiting, which
- 6:21Speaker 2: limited their use. Microdosing, however, is a different story. While
- 6:26Speaker 2: anecdotal reports suggest cognitive benefits, it's uncharted territory. To raise
- 6:31Speaker 2: a risk of long-term side effects, and we need more
- 6:35Speaker 2: rigorous clinical trials to confirm the safety and efficacy.
- 6:38Speaker 1: Speaking of which, what are some of the key research
- 6:42Speaker 1: areas that need more exploration?
- 6:44Speaker 2: That's a good point. One major area is understanding the
- 6:48Speaker 2: mechanisms of GLP-1 in higher cognitive functions. we need to
- 6:53Speaker 2: explore how it affects memory and learning processes more deeply. Additionally,
- 6:58Speaker 2: to raise a need to develop targeted receptor agonists that
- 7:01Speaker 2: can modulate its effects without the adverse side effects seen
- 7:05Speaker 2: in broader spectrum therapies.
- 7:07Speaker 1: Exactly. Bringing us back to the idea of microdosing. Could
- 7:11Speaker 1: this be the future of cognitive enhancement, or is it
- 7:15Speaker 1: too risky?
- 7:16Speaker 2: It's certainly interesting, but it raises ethical and practical questions.
- 7:21Speaker 2: We need more data from controlled trials to see if
- 7:24Speaker 2: the benefits outweigh the risks. For now, it's more of
- 7:28Speaker 2: a speculative area with a lot of potential, but also
- 7:32Speaker 2: a lot of uncertainty.
- 7:33Speaker 1: The contradictions when it comes to GLP-1 are fascinating, aren't they?
- 7:39Speaker 1: On one hand, it's a powerhouse in diabetes management, but
- 7:42Speaker 1: on the other, it's being explored for cognitive enhancement. How
- 7:47Speaker 1: do we navigate these conflicting roles?
- 7:49Speaker 2: Exactly. And it's not just about the contradiction. There are
- 7:53Speaker 2: also ethical and practical challenges. For instance, if GLP-1 might
- 7:58Speaker 2: have cognitive benefits, why do the drugs come with such
- 8:01Speaker 2: side effects? How do we reconcile the risks with potential rewards?
- 8:05Speaker 1: Right. And that's the crucial nuance here. The side effects
- 8:10Speaker 1: reported with GLP-1 drugs are significant, like nausea and vomiting.
- 8:17Speaker 1: But in micro, dosing, people are reporting fewer, if any.
- 8:22Speaker 1: Side effects. This leads to the question, is it safe
- 8:26Speaker 1: to use GLP-1 for cognitive enhancement?
- 8:30Speaker 2: It's a tricky question. Microdosing is largely unregulated and unproven
- 8:35Speaker 2: in humans. The ethical concerns are immense. How can you
- 8:38Speaker 2: ethically test something that might help cognitive function in one
- 8:42Speaker 2: group if it's only available to those willing to self-experiment?
- 8:46Speaker 1: Exactly. Which brings up an interesting contradiction. We have both
- 8:51Speaker 1: anecdotal evidence and some animal studies suggesting GLP-1 might improve
- 8:57Speaker 1: memory and reward pathways. But clinical trials in humans are
- 9:01Speaker 1: still sorely lacking. It's like we are in this weird limbo.
- 9:06Speaker 2: It's a perfect example of the gap between preclinical and
- 9:09Speaker 2: human data. Animal studies might show promising results, but human
- 9:13Speaker 2: reactions can be unpredictable. The transition from lab to real-world
- 9:18Speaker 2: application is both exciting and fraught with challenges.
- 9:21Speaker 1: And it's not just about the data. There are also
- 9:24Speaker 1: public health implications. Expanding GLP-1 use beyond diabetic patients could
- 9:30Speaker 1: have massive societal impacts, but we need to be cautious.
- 9:35Speaker 1: The risks and benefits must be carefully balanced.
- 9:37Speaker 2: Precisely. Another angle is the debate over artificial sweeteners. There
- 9:42Speaker 2: are concerns they might interact with GLP-1 in a detrimental way,
- 9:47Speaker 2: especially in early life. This raises questions about diet and
- 9:51Speaker 2: brain development that we are only just beginning to explore.
- 9:54Speaker 1: And here is the issue of targeted receptor agonists. Wouldn't
- 9:58Speaker 1: it be better to develop drugs that specifically target the
- 10:01Speaker 1: neural circuits involved in cognition without all the side effects?
- 10:06Speaker 1: That way, we can avoid the risk of disrupting other functions.
- 10:09Speaker 2: Agreed. Microdosing might hint at this potential, but it's not
- 10:13Speaker 2: a long-term solution. We need to prioritize research that can
- 10:17Speaker 2: lead to more precise therapies. The challenge is finding that
- 10:21Speaker 2: sweet spot between effectiveness and safety.
- 10:23Speaker 1: It's a complex puzzle we are trying to solve, but
- 10:26Speaker 1: with careful, controlled research, we might be able to unlock
- 10:29Speaker 1: some of GLP-1's true potential without the pitfalls. The future
- 10:35Speaker 1: of cognitive enhancement might lie in these nuanced investigations.
- 10:39Speaker 2: Absolutely. The more we understand about GLP-1, the closer we
- 10:44Speaker 2: get to refining its applications. But we must proceed with caution.
- 10:48Speaker 2: There are too many unknowns to ignore.
- 10:51Speaker 1: So, Thomas, let's dive deeper into some of the emerging
- 10:54Speaker 1: questions and the expert quotes surrounding DLP-1, S-impact on higher
- 11:00Speaker 1: cognitive functions, especially micro, dosing, and artificial sweeteners. What are
- 11:06Speaker 1: your thoughts on how DLP-1 might be affecting these areas?
- 11:10Speaker 2: Great question, Trachel. TreeRays a lot of intrigue right now.
- 11:15Speaker 1: Dr.
- 11:15Speaker 2: Huberman mentioned that habitual exposure to artificial sweeteners can disrupt
- 11:20Speaker 2: metabolic processes and even memory development, particularly in children. This
- 11:26Speaker 2: adds another layer of complexity to the GLP-1 story. How
- 11:31Speaker 2: do you think this applies to something like micro, dosing
- 11:34Speaker 2: GLP-1 for cognitive enhancement?
- 11:37Speaker 1: I agree. It's fascinating how many intertwined variables are at
- 11:41Speaker 1: play here. For instance, The quote from Dr. Kanowski about
- 11:45Speaker 1: memory impairments in animals struck a chord. It raises questions
- 11:50Speaker 1: about how these substances interact with our reward pathways and
- 11:54Speaker 1: memory systems. Do you think this could have implications for
- 11:58Speaker 1: how we approach cognitive enhancement?
- 12:01Speaker 2: Definitely. The potential for GLP-1 to modulate reward pathways and
- 12:06Speaker 2: possibly enhance memory could be a game changer. However, we
- 12:11Speaker 2: need to tread carefully.
- 12:12Speaker 1: Dr.
- 12:12Speaker 2: Huberman's work on the vagus nerve and GLI-LP-1's central role
- 12:18Speaker 2: in appetite control suggests that any manipulation of GLI-LP-1 could
- 12:22Speaker 2: have broad effects on brain function, not just in the gut.
- 12:26Speaker 2: This means that micro, dosed ELP-1 might not be as
- 12:31Speaker 2: benign as some speculate.
- 12:32Speaker 1: Right. And that's the crucial nuance here. We can't just
- 12:36Speaker 1: dismiss the potential benefits without understanding the full range of
- 12:40Speaker 1: risks and side effects. How do we move forward with
- 12:44Speaker 1: research that balances these concerns?
- 12:46Speaker 2: That's a tough call. One idea I have been pondering
- 12:50Speaker 2: is the development of targeted DLP-1 receptor agonists. By creating
- 12:55Speaker 2: drugs that specifically target the cognitive pathways, we might mitigate
- 12:59Speaker 2: some of the more problematic side effects. Think of it
- 13:02Speaker 2: as a kind of precision medicine for the brain.
- 13:05Speaker 1: Precision medicine indeed. And what about the long-term exposure and
- 13:09Speaker 1: its effects? We know GLP-1 has broad actions. So what
- 13:15Speaker 1: are your thoughts on how extended use might play out
- 13:18Speaker 1: in humans?
- 13:19Speaker 2: The long-term effects are a real wild card. We need
- 13:22Speaker 2: more data from human studies to understand the real-world impacts.
- 13:27Speaker 2: The animal models are fascinating, but they don't always translate perfectly. Plus,
- 13:32Speaker 2: as Dr. Kanowski said, preclinical data often has limitations when
- 13:36Speaker 2: it comes to humans.
- 13:37Speaker 1: Exactly. Those discrepancies between preclinical and clinical data are a
- 13:42Speaker 1: major sticking point. And let's not forget the ethical considerations
- 13:47Speaker 1: around microdosing. How do we ensure that these practices are
- 13:52Speaker 1: safe and effective without causing harm?
- 13:54Speaker 2: Very true. The ethics of microdosing are complex. Randomized controlled
- 14:00Speaker 2: trials could provide crucial insights, but would also require robust
- 14:04Speaker 2: regulatory oversight. We need to weigh the potential benefits against
- 14:09Speaker 2: the risks, especially when it comes to something as potent
- 14:12Speaker 2: as GLP-1.
- 14:14Speaker 1: Agreed. It's all about finding that sweet spot, isn't it?
- 14:18Speaker 1: We need to keep pushing the boundaries of knowledge without
- 14:21Speaker 1: compromising on safety and ethical standards. Speaking of which, what
- 14:25Speaker 1: do you think the future outlook looks like for GLP-1 research?
- 14:29Speaker 2: It's exciting to think about where this could go. The
- 14:32Speaker 2: potential for GLP-1 in treating conditions. like substance abuse and
- 14:37Speaker 2: memory disorders, is particularly compelling. However, we need sustained, high-quality
- 14:43Speaker 2: research to back these claims up. It's a bit of
- 14:46Speaker 2: a chicken and egg problem. We need to prove the
- 14:49Speaker 2: drugs' efficacy before they can be widely used, but without real,
- 14:53Speaker 2: world applications, we can't fully understand their full potential. True.
- 14:58Speaker 1: And with all these open questions, it's clear that further
- 15:01Speaker 1: research is crucial. we should focus on developing more specific
- 15:05Speaker 1: therapies and conducting rigorous clinical trials to get a better
- 15:09Speaker 1: grasp of GLP-1S multifaceted roles. It's a complex puzzle, but
- 15:16Speaker 1: one we can definitely work towards solving. The potential of
- 15:19Speaker 1: GLP-1 for cognitive enhancement is indeed intriguing, but let's dive
- 15:25Speaker 1: into the ethical considerations. How do we ensure that its
- 15:29Speaker 1: therapeutic applications don't lead to misuse or unintended consequences.
- 15:34Speaker 2: That's a crucial point, Rachel. For instance, the idea of
- 15:38Speaker 2: microdosing for cognitive benefits is alluring, but also fraught with
- 15:43Speaker 2: ethical dilemmas to raise a balance between personal freedom and
- 15:47Speaker 2: public health. What if these microdosed individuals are driving or
- 15:51Speaker 2: operating heavy machinery? The potential risks are significant, especially in
- 15:56Speaker 2: an unregulated environment.
- 15:58Speaker 1: Right. And consider the broader implications for personalized therapy. If GLP-1,
- 16:04Speaker 1: SFX are validated, it could revolutionize cognitive therapies, offering tailored
- 16:10Speaker 1: treatments for different cognitive needs. But who would have access
- 16:14Speaker 1: to these treatments? And would they be affordable? We need
- 16:18Speaker 1: to tread carefully.
- 16:19Speaker 2: Exactly. A perfect example of personalized therapy gone awry if
- 16:23Speaker 2: not managed properly. And speaking of costs, we should remember
- 16:26Speaker 2: that pharmaceutical innovation often leads to high prices. Insurance companies
- 16:31Speaker 2: might restrict access based on cost. This could exacerbate health disparities,
- 16:36Speaker 2: where only the wealthy benefit from such advancements.
- 16:39Speaker 1: That's a valid concern. The potential for GLP-1 to bridge
- 16:42Speaker 1: gaps in public health is immense, but it also risks
- 16:46Speaker 1: widening the gap between those who can afford it and
- 16:48Speaker 1: those who can't. We need robust public health policies to
- 16:51Speaker 1: ensure equitable access. What do you think about incorporating DLP-1
- 16:56Speaker 1: treatments into public health programs? Thomas?
- 17:00Speaker 2: That's a radical idea with potential. Public health programs could
- 17:04Speaker 2: address the disparities by providing DLP-1 treatments at a lower
- 17:08Speaker 2: cost or even for free. However, we must also consider
- 17:12Speaker 2: the long-term side effects and ensure that the focus remains
- 17:15Speaker 2: on the intended therapeutic benefits rather than profit. This will
- 17:19Speaker 2: require stringent regulations and oversight.
- 17:22Speaker 1: Absolutely. And let's not forget the research gaps. While GLP-1
- 17:27Speaker 1: shows promise, we need more robust clinical trials to understand
- 17:31Speaker 1: its full impact on the brain. We should push for
- 17:34Speaker 1: more studies that specifically focus on cognitive enhancement, especially in
- 17:39Speaker 1: non-obese populations who might benefit from these interventions.
- 17:43Speaker 2: Agreed, and the data must be transparent. Transparency will help
- 17:47Speaker 2: build trust and ensure that the public is informed about
- 17:50Speaker 2: both the benefits and potential risks. We should encourage open
- 17:54Speaker 2: dialogue among researchers and policymakers to address these challenges and
- 17:58Speaker 2: pave the way for responsible innovation.
- 18:00Speaker 1: That sounds like a well-rounded approach. We can't rush into
- 18:04Speaker 1: widespread application without ensuring that we have the right understanding
- 18:08Speaker 1: and infrastructure in place. Speaking of which, how do we
- 18:11Speaker 1: effectively disseminate this research to the public without causing alarm
- 18:15Speaker 1: or misunderstanding?
- 18:17Speaker 2: Communication is key. We need to educate the public and
- 18:20Speaker 2: clinicians about the current state of research and its limitations. Clear,
- 18:25Speaker 2: evidence-based communication will help mitigate misunderstandings and promote responsible use.
- 18:31Speaker 2: It's a marathon, not a sprint.
- 18:33Speaker 1: Exactly. And let's keep the conversation going. The potential of
- 18:38Speaker 1: GLP-1 is vast, but so are the challenges. Let's ensure
- 18:43Speaker 1: that everyone, regardless of their financial situation— has a chance
- 18:48Speaker 1: to benefit from this exciting research. That brings us to
- 18:51Speaker 1: the end of today's episode. Thank you so much for
- 18:54Speaker 1: spending part of your day with me. If you found
- 18:56Speaker 1: this episode's tips helpful and want to make sure you
- 18:59Speaker 1: don't miss the next conversation, please take a quick second
- 19:02Speaker 1: to hit that subscribe or follow button on whatever platform
- 19:05Speaker 1: you are listening on. It's a completely free way to
- 19:08Speaker 1: support the show and helps more people find us. This
- 19:11Speaker 1: podcast is independently produced, so if you are ever in
- 19:15Speaker 1: a position where you would like to help keep it running,
- 19:18Speaker 1: We do accept small donations. You can find a link
- 19:21Speaker 1: right in the episode description below to buy us a
- 19:24Speaker 1: coffee or contribute what you can. Every bit genuinely helps.
- 19:29Speaker 1: Take care of yourself, stay balanced, and we will talk
- 19:32Speaker 1: again soon.